TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23102189

Group type: EXPERIMENTAL
Intervention: Fluticasone/formoterol 250/10 μg twice daily
Number of subjects: 279

Group type: COMPARATOR
Intervention: Budesonide/formoterol 400/12 μg twice daily
Number of subjects: 279
Study: 20838819

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Left-Lateral Decubitus position
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Right-Lateral Decubitus position
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Sitting position
Number of subjects: 13
Study: 17947725

Group type: EXPERIMENTAL
Intervention: FOLFIRI
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: mIFL
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: CapeIRI
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: FOLFIRI+Bev
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: mIFL+Bev
Number of subjects: 430
Study: 16118599

Group type: EXPERIMENTAL
Intervention: Metronidazole/nystatin ovules
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metronidazole gel
Number of subjects: 0
Study: 12120776

Group type: EXPERIMENTAL
Intervention: Robot Carbides (RC)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Super-Snap system (SS)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: OneGloss (OG)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: CompoSite Points (CS)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Fuji II LC
Number of subjects: 32

Group type: COMPARATOR
Intervention: Photac-Fil Quick (ESPE)
Number of subjects: 32
Study: 10320241

Group type: EXPERIMENTAL
Intervention: Heparin-coated circuits (HCCs)
Number of subjects: 886

Group type: COMPARATOR
Intervention: Conventional circuits (control group)
Number of subjects: 886
Study: 8729093

Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) supplementation
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Fish oil concentrate (FOC) supplementation
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA) supplementation
Number of subjects: 49

Group type: COMPARATOR
Intervention: Olive oil (OO) placebo
Number of subjects: 49
Study: 1679626

Group type: EXPERIMENTAL
Intervention: Massed treatment condition (shorter intersession intervals)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Spaced treatment condition (longer intersession intervals)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Concordance between behavioural, cognitive, and physiological anxiety responses
Number of subjects: 0
Study: 6627195

Group type: EXPERIMENTAL
Intervention: Covert behavior rehearsal in a relaxed condition
Number of subjects: 33

Group type: COMPARATOR
Intervention: Relaxation only
Number of subjects: 33

Group type: COMPARATOR
Intervention: No preparation at all
Number of subjects: 33
Study: 30882234

Group type: EXPERIMENTAL
Intervention: ICD implantation
Number of subjects: 188

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 188
Study: 29693310

Group type: EXPERIMENTAL
Intervention: High-fat diet
Number of subjects: 692

Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 692

Group type: EXPERIMENTAL
Intervention: High-fat diet with baseline methylation at cg26663590
Number of subjects: 692

Group type: EXPERIMENTAL
Intervention: Low-fat diet with baseline methylation at cg26663590
Number of subjects: 692
Study: 28128751

Group type: EXPERIMENTAL
Intervention: Ioxaglate
Number of subjects: 20

Group type: COMPARATOR
Intervention: Isotonic saline solution (NaCl)
Number of subjects: 20
Study: 24582547

Group type: EXPERIMENTAL
Intervention: Sat Pad with STIR
Number of subjects: 25

Group type: COMPARATOR
Intervention: DWI using STIR
Number of subjects: 25
Study: 22113068

Group type: EXPERIMENTAL
Intervention: Dietary intake of 100 g of blanched Agaricus bisporus white button mushroom daily for 1 week
Number of subjects: 24

Group type: COMPARATOR
Intervention: Normal daily diet without WBM (control group)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Dietary intake of 100 g of blanched Agaricus bisporus white button mushroom
Number of subjects: 24
Study: 19945492

Group type: EXPERIMENTAL
Intervention: Chickpea supplemented diet (average 104 g/day)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Habitual diet
Number of subjects: 42
Study: 17494881

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide and steroids (prednisolone) for 6 months
Number of subjects: 93

Group type: COMPARATOR
Intervention: Supportive treatment (control group)
Number of subjects: 93
Study: 16327614

Group type: COMPARATOR
Intervention: Preoperative single intravenous dose of antibiotics
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Combined regimen with preoperative single-shot antibiotics plus a postoperative 7-day course of oral antibiotics
Number of subjects: 200
Study: 11872885

Group type: EXPERIMENTAL
Intervention: Weight-based heparin nomogram
Number of subjects: 206
Study: 11453902

Group type: EXPERIMENTAL
Intervention: Adapalene 0.1%
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Tretinoin 0.025%
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Clindamycin 1%
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Clindamycin 1% + Tretinoin 0.025%
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Benzoyl peroxide 5%
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Benzoyl peroxide 5% + Erythromycin 2%
Number of subjects: 6
Study: 9495223

Group type: EXPERIMENTAL
Intervention: Stavudine 40 mg single oral dose
Number of subjects: 12
Study: 7520078

Group type: EXPERIMENTAL
Intervention: Wound drainage
Number of subjects: 171

Group type: COMPARATOR
Intervention: No wound drainage
Number of subjects: 171
Study: 2497168

Group type: EXPERIMENTAL
Intervention: Theophylline (300 mg, sustained-release, Theo-Dur)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Cromolyn sodium (10 mg)
Number of subjects: 6
Study: 1092420

Group type: EXPERIMENTAL
Intervention: Intermittent positive-pressure ventilation (I.P.P.V.) of 10 mg of salbutamol
Number of subjects: 78

Group type: COMPARATOR
Intervention: Conventional dose (200 mug) from a pressurized canister
Number of subjects: 78
Study: 447817

Group type: EXPERIMENTAL
Intervention: Melatonin (250 mg every 8 h over a period of 40 h)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 31425700

Group type: EXPERIMENTAL
Intervention: 13 mg/day total MXans
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: 27 mg/day total MXans
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 30136102

Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg twice daily
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Tramadol ER 200 mg in the morning, 100 mg in the evening
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Co-administration of pregabalin 150 mg and tramadol ER 200 mg in the morning, and pregabalin 150 mg and tramadol ER 100 mg in the evening
Number of subjects: 21
Study: 26728611

Group type: EXPERIMENTAL
Intervention: Etoricoxib (90 mg once daily for nine days)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Diclofenac (75 mg twice daily for nine days)
Number of subjects: 100
Study: 25141536

Group type: EXPERIMENTAL
Intervention: Home-based exercise with self-manual therapy
Number of subjects: 43

Group type: COMPARATOR
Intervention: Home-based exercise without self-manual therapy
Number of subjects: 43
Study: 22230651

Group type: EXPERIMENTAL
Intervention: Risperidone (3.2±2.3mg/day)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Olanzapine (9.2±4.9mg/day)
Number of subjects: 35
Study: 20122041

Group type: EXPERIMENTAL
Intervention: 6-month education program for nursing staff
Number of subjects: 184

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 184
Study: 17644512

Group type: EXPERIMENTAL
Intervention: Anti-anginal drug therapy in addition to risk factor control (MED)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Risk factor control-only (RFC)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Anti-anginal drug therapy (MED)
Number of subjects: 54
Study: 16227030

Group type: EXPERIMENTAL
Intervention: 2.4 g amino acids (AA)/(kg.d) from birth onward
Number of subjects: 135

Group type: COMPARATOR
Intervention: Glucose only during the first day with a stepwise increase in AA intake to 2.4 g AA/(kg.d) on day 3
Number of subjects: 135
Study: 12058521

Group type: EXPERIMENTAL
Intervention: Health education program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard individual intervention program
Number of subjects: 0
Study: 10086669

Group type: EXPERIMENTAL
Intervention: Cisapride, 10 mg q.i.d. for 4 days
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 7648705

Group type: EXPERIMENTAL
Intervention: cA2, a chimaeric anti-TNF-α monoclonal antibody (MoAb)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 2033450

Group type: EXPERIMENTAL
Intervention: Irradiation plus MOPP (nitrogen mustard, vincristine, procarbazine, and prednisone)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radiation therapy alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Irradiation plus MOPP
Number of subjects: 0
Study: 6453988

Group type: EXPERIMENTAL
Intervention: Cooperative condition
Number of subjects: 30

Group type: COMPARATOR
Intervention: Competitive condition
Number of subjects: 30

Group type: COMPARATOR
Intervention: Individualistic condition
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Handicapped students
Number of subjects: 30
Study: 31955940

Group type: EXPERIMENTAL
Intervention: Ultralong, 6.35-cm, 20-gauge ultrasonographically guided intravenous peripheral catheters
Number of subjects: 257

Group type: COMPARATOR
Intervention: Standard long, 4.78-cm, 20-gauge ultrasonographically guided intravenous peripheral catheters
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Catheters with greater than 2.75 cm inserted
Number of subjects: 257

Group type: COMPARATOR
Intervention: Catheters with less than or equal to 2.75 cm inserted
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Ultralong catheters
Number of subjects: 257

Group type: COMPARATOR
Intervention: Standard long catheters
Number of subjects: 257
Study: 30845037

Group type: EXPERIMENTAL
Intervention: Single dose of prophylactic antibiotics (n = 4,523)
Number of subjects: 20682
Study: 28110953

Group type: EXPERIMENTAL
Intervention: Decision Aid (DA) - PCI Choice
Number of subjects: 13
Study: 26367803

Group type: EXPERIMENTAL
Intervention: Exercise intervention (self-regulatory strategies, role model support)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Stress management intervention (active control)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Exercise intervention (with role model contact)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Exercise intervention (without role model contact)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Both interventions (exercise and stress management)
Number of subjects: 72
Study: 24386952

Group type: EXPERIMENTAL
Intervention: Cetuximab followed by pemetrexed at progression (Arm A)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Concurrent cetuximab and pemetrexed (Arm B)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Cetuximab therapy
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Serum proteomic classifier
Number of subjects: 55
Study: 21692101

Group type: EXPERIMENTAL
Intervention: Zinc sulfate
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 19782264

Group type: EXPERIMENTAL
Intervention: Cilnidipine
Number of subjects: 32

Group type: COMPARATOR
Intervention: Nifedipine retard
Number of subjects: 32
Study: 18372700

Group type: EXPERIMENTAL
Intervention: Head-down bed rest (HDBR) for 60 days
Number of subjects: 24
Study: 16314772

Group type: EXPERIMENTAL
Intervention: Douching intervention group
Number of subjects: 275

Group type: COMPARATOR
Intervention: Comparison condition (healthy eating and nutrition)
Number of subjects: 275
Study: 11834660

Group type: EXPERIMENTAL
Intervention: CPAP trial of 5 cm H(2)O and FIO(2) of 40% (condition 1)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: CPAP trial of 5 cm H(2)O and FIO(2) of 21% (condition 2)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Spontaneously breathing room air trial without ventilatory support (condition 3)
Number of subjects: 33
Study: 10192590

Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 600

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study: 7578729

Group type: EXPERIMENTAL
Intervention: Drug regimen 1 (3 doses of 3-5 mg/kg, on days 0, 3, and 10)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Drug regimen 2 (6 doses of 3-5 mg/kg, on days 0, 3, 6, 8, 10, and 13)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Rescue therapy with L-AmB alone (3 mg/kg daily for 10 days)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Regimen 3 (4 doses of 4-5 mg/kg, on days 0, 2, 5, and 7)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Optimal regimen of L-AmB
Number of subjects: 49
Study: 2339368

Group type: EXPERIMENTAL
Intervention: F XIII concentrate administered within 6 hours after delivery
Number of subjects: 58

Group type: COMPARATOR
Intervention: Non-treated group
Number of subjects: 58
Study: 565418

Group type: EXPERIMENTAL
Intervention: Isotonic amino acid infusions
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Preoperative keto-adaptation by a carbohydrate-free, oral protein diet
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Postoperative amino acid infusions only
Number of subjects: 17

Group type: COMPARATOR
Intervention: 5 percent dextrose infusions
Number of subjects: 17
Study: 31984620

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 33
Study: 29315160

Group type: EXPERIMENTAL
Intervention: High-dose vitamin D (1200 IU)
Number of subjects: 400
Study: 26252780

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 300
Study: 25422826

Group type: EXPERIMENTAL
Intervention: 5-mm short implants
Number of subjects: 30

Group type: COMPARATOR
Intervention: 10-mm long implants
Number of subjects: 30
Study: 21912983

Group type: EXPERIMENTAL
Intervention: Er:YAG laser treatment (2 Hz/32.4 mJ/5.9 J/cm(2))
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser treatment (0.25 W/4.4 J/cm(2))
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser treatment (0.50 W/8.9 J/cm(2))
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 28
Study: 20523083

Group type: EXPERIMENTAL
Intervention: Platinum-based first-line chemotherapy
Number of subjects: 390

Group type: COMPARATOR
Intervention: Non-platinum-based first-line chemotherapy
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Platinum-based second-line chemotherapy
Number of subjects: 390

Group type: COMPARATOR
Intervention: Non-platinum-containing second-line chemotherapy
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Both sequences (platinum-based first-line followed by non-platinum second-line and vice versa)
Number of subjects: 390
Study: 18440702

Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS) ON
Number of subjects: 16

Group type: COMPARATOR
Intervention: Spinal cord stimulation (SCS) OFF
Number of subjects: 16
Study: 16188050

Group type: EXPERIMENTAL
Intervention: Aspirin-resistant group
Number of subjects: 256

Group type: COMPARATOR
Intervention: Aspirin-sensitive group
Number of subjects: 256
Study: 11813818

Group type: EXPERIMENTAL
Intervention: Qualitative assessment of emphysema using CT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quantitative CT in the evaluation of patients with emphysema for surgery and drug therapy
Number of subjects: 0
Study: 10435730

Group type: EXPERIMENTAL
Intervention: Initiating leukapheresis based on rising WBC and platelet counts
Number of subjects: 190
Study: 7554633

Group type: EXPERIMENTAL
Intervention: Enoxaparin 30 mg twice daily
Number of subjects: 1940

Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg once daily
Number of subjects: 1940

Group type: EXPERIMENTAL
Intervention: Enoxaparin 10 mg once daily
Number of subjects: 1940

Group type: COMPARATOR
Intervention: Low dose unfractionated heparin (5000 IU 3 times daily or 7500 IU twice daily)
Number of subjects: 1940

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1940

Group type: EXPERIMENTAL
Intervention: Enoxaparin (30 mg twice daily, 40 mg once daily, 10 mg once daily)
Number of subjects: 1940

Group type: COMPARATOR
Intervention: Low dose unfractionated heparin
Number of subjects: 1940
Study: 1691377

Group type: EXPERIMENTAL
Intervention: Supine position after 1.5 hours rest
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sitting position after 1.5 hours rest
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Supine position after 2 hours rest
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sitting position after 2 hours rest
Number of subjects: 21
Study: 373841

Group type: EXPERIMENTAL
Intervention: Cephaloridine (3 doses, continued for 12 hours post-surgery)
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Flucloxacillin (2-week regimen, continued for 14 days post-surgery)
Number of subjects: 297
Study: 31061432

Group type: EXPERIMENTAL
Intervention: 99mtechnetium plus indocyanine green (ICG)
Number of subjects: 99

Group type: COMPARATOR
Intervention: 99mtechnetium alone
Number of subjects: 99
Study: 28639118

Group type: EXPERIMENTAL
Intervention: T0001 (10, 20, 35, 50, 65, or 75 mg)
Number of subjects: 56
Study: 25938155

Group type: EXPERIMENTAL
Intervention: Distal incision flap (Group A)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Angular incision flap (Group B)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 400
Study: 23725215

Group type: EXPERIMENTAL
Intervention: Long-acting beta-agonists
Number of subjects: 591
Study: 21557649

Group type: EXPERIMENTAL
Intervention: aIAT congruent block (associating intentions with true sentences)
Number of subjects: 0

Group type: COMPARATOR
Intervention: aIAT incongruent block (associating intentions with false sentences)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison of intentions with hopes
Number of subjects: 0
Study: 19347033

Group type: EXPERIMENTAL
Intervention: Achieved systolic/diastolic BP (SBP/DBP) <130/75-79 mm Hg in patients with LVH
Number of subjects: 4553

Group type: EXPERIMENTAL
Intervention: Achieved SBP/DBP <130/75-79 mm Hg in patients with DM or CKD
Number of subjects: 4553
Study: 16863716

Group type: EXPERIMENTAL
Intervention: Revised food frequency questionnaire (FFQ)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Fred Hutchinson FFQ
Number of subjects: 105
Study: 12755836

Group type: EXPERIMENTAL
Intervention: H2-receptor antagonist (300 mg nizatidine)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Proton pump inhibitor (30 mg lansoprazole)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: H2-receptor antagonists (overall efficacy from 12 studies)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Proton pump inhibitors (overall efficacy from 12 studies)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: H2-receptor antagonist (clarithromycin-containing regimens)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Proton pump inhibitors (non-clarithromycin-containing trials)
Number of subjects: 101
Study: 11052441

Group type: EXPERIMENTAL
Intervention: Nitroglycerin (NTG) 2 microg/kg/min for 6 hours after extubation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups (NTG and placebo)
Number of subjects: 40
Study: 9071052

Group type: EXPERIMENTAL
Intervention: Caffeine, dosage and duration not specified
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group, not specified
Number of subjects: 0
Study: 7529464

Group type: EXPERIMENTAL
Intervention: High-dose aprotinin (2 million units loading dose, 2 million units added to the CPB prime, and 500,000 units/hr maintenance infusion)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 3164442

Group type: EXPERIMENTAL
Intervention: Intravenous gammaglobulin (ivGG) infusion
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normal sera
Number of subjects: 20
Study: 31705201

Group type: EXPERIMENTAL
Intervention: myMCT
Number of subjects: 80

Group type: COMPARATOR
Intervention: waitlist control
Number of subjects: 80
Study: 30262148

Group type: EXPERIMENTAL
Intervention: Dietitian‐led Dietary Approaches to Stop Hypertension diet and physical activity coaching
Number of subjects: 281

Group type: COMPARATOR
Intervention: Usual care (web-watcher)
Number of subjects: 281
Study: 25793429

Group type: EXPERIMENTAL
Intervention: Nurse-led breathing training program (8 sessions)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 57
Study: 23672818

Group type: EXPERIMENTAL
Intervention: Atomoxetine once daily (n = 32)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: IR-methylphenidate (n = 31)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Comparison of both interventions
Number of subjects: 63
Study: 20435261

Group type: EXPERIMENTAL
Intervention: Bypass surgery (BSX)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Balloon angioplasty (BAP)
Number of subjects: 0
Study: 18972727

Group type: EXPERIMENTAL
Intervention: Scalp-acupuncture plus exercise therapy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Exercise therapy
Number of subjects: 80
Study: 16359825

Group type: EXPERIMENTAL
Intervention: 10 min of moderate intensity cycle ergometry (n=18)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo control condition (very light intensity cycle ergometry, n=19)
Number of subjects: 37
Study: 12816263

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine infiltration at Mayfield skull‐pin sites
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo infiltration at Mayfield skull‐pin sites
Number of subjects: 30
Study: 11008326

Group type: EXPERIMENTAL
Intervention: L-Tryptophan (500 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 8763553

Group type: EXPERIMENTAL
Intervention: Teacher-directed instruction
Number of subjects: 4

Group type: COMPARATOR
Intervention: Computer-assisted instruction
Number of subjects: 4